Insight into SARS-CoV-2 Omicron variants in Saudi Arabian genomic isolates

References

1. 1.↵
   1. Janik E,
   2. Niemcewicz M,
   3. Podogrocki M,
   4. Majsterek I,
   5. Bijak M.

   The emerging concern and interest SARS-CoV-2 variants. Pathogens 2021; 10: 633.

   OpenUrl
2. 2.↵
   1. Jogalekar MP,
   2. Veerabathini A,
   3. Gangadaran P.

   SARS-CoV-2 variants: A double-edged sword? Exp Biol Med (Maywood) 2021; 246: 1721–1726.

   OpenUrl
3. 3.↵
   1. Winger A,
   2. Caspari T.

   The spike of concern-the novel variants of SARS-CoV-2. Viruses 2021; 13: 1002.

   OpenUrl
4. 4.↵
   1. Lino A,
   2. Cardoso MA,
   3. Martins-Lopes P,
   4. Gonçalves HMR.

   Omicron - The new SARS-CoV-2 challenge? Rev Med Virol 2022; 32: e2358.

   OpenUrl
5. 5.↵
   1. Kamil JP.

   Virus variants: GISAID policies incentivize surveillance in global south. Nature 2021 May 18;593: 341–341.

   OpenUrl
6. 6.↵
   1. Elbe S,
   2. Buckland‐Merrett G. Data

   , disease and diplomacy: GISAID’s innovative contribution to global health. Global Challenges 2017; 1: 33–46.

   OpenUrl
7. 7.↵
   1. Chen J,
   2. Wang R,
   3. Gilby NB,
   4. Wei GW.

   Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model 2022; 62: 412–422.

   OpenUrlPubMed
8. 8.
   1. Khan A,
   2. Waris H,
   3. Rafique M,
   4. Suleman M,
   5. Mohammad A,
   6. Ali SS, et al.

   The Omicron (B.1.1.529) variant of SARS-CoV-2 binds to the hACE2 receptor more strongly and escapes the antibody response: Insights from structural and simulation data. International Journal of Biological Macromolecules 2022; 200: 438–448.

   OpenUrlCrossRef
9. 9.↵
   1. Wang R,
   2. Chen J,
   3. Hozumi Y,
   4. Yin C,
   5. Wei GW.

   Emerging vaccine-breakthrough SARS-CoV-2 variants. ArXiv. 2021; arXiv: 2109.04509v1.
10. 10.↵
    1. Abdool Karim SS,
    2. de Oliveira T.

    New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications. N Engl J Med 2021; 384: 1866–1868.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Tartof SY,
    2. Slezak JM,
    3. Fischer H,
    4. Hong V,
    5. Ackerson BK,
    6. Ranasinghe ON, et al.

    effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 2021; 398: 1407–1416.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Collie S,
    2. Champion J,
    3. Moultrie H,
    4. Bekker LG,
    5. Gray G.

    Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N Engl J Med 2022; 386: 494–496.

    OpenUrlPubMed
13. 13.↵
    1. Andrews N,
    2. Stowe J,
    3. Kirsebom F,
    4. Toffa S,
    5. Rickeard T,
    6. Gallagher E, et al.

    Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. New England Journal of Medicine 2022; 386: 1532–1546.

    OpenUrlCrossRefPubMed